Key facts
- Hedge fund exposure to U.S. healthcare stocks was near a five-year high last week.
- Goldman Sachs noted increased hedge fund purchases in healthcare equipment, life sciences tools, and pharmaceuticals.
- AI is being utilized as a tool in drug discovery, boosting research productivity.
- Projected deal volumes in the sector could reach $173 billion by 2026.
- The FDA's expedited approval process has led to the highest number of new drug approvals since 2020.
- Specialized healthcare hedge funds have outperformed generalist funds, with returns near 40% in a recent period.
Hedge fund positioning in U.S. healthcare stocks has approached a five-year peak, driven by expectations of AI-fueled advancements and robust financing conditions, according to a note from Goldman Sachs. The S&P 500 healthcare index has risen nearly 5% year-to-date, with European counterparts up around 2%.
Hedge funds have been increasing their exposure to the sector for two consecutive weeks, with significant purchases noted in healthcare equipment and supplies, life sciences tools, and pharmaceuticals. Goldman Sachs previously highlighted AI's role in accelerating drug discovery as a key catalyst, projecting deal volumes to reach $173 billion by 2026, the highest since 2019.
Further supporting the sector's momentum, the Food and Drug Administration has expedited its approval processes, leading to the highest number of new drug approvals since 2020. While regulatory volatility has increased this year, smaller pharmaceutical companies are reportedly more willing to accept higher discounts on acquisitions for deal certainty, creating a favorable environment for mergers and acquisitions.
Specialized healthcare hedge funds have demonstrated strong performance, posting returns near 40% between August 2025 and April 2026, significantly outperforming generalist stock trading hedge funds, which returned 17% in the same period. The trend of dedicated healthcare funds is also growing, with 24% of new fund launches this year focusing on the sector, the highest proportion since at least 2009. Approximately $283 billion of the $1 trillion managed by equity hedge funds is allocated to healthcare specialists.